Sign Out
Amaryl is contraindicated for the treatment of insulin-dependent (type I) diabetes mellitus (e.g. for the treatment of diabetics with a history of ketoacidosis), of diabetic ketoacidosis, or of diabetic precoma or coma (hyperglycemic hyperosmolar nonketotic syndrome).
Amaryl must not be used in patients hypersensitive to Glimepiride, other sulfonylureas, other sulfonamides, or to any of the Excipients (see "Description").
No experience has been gained concerning the use of Amaryl in patients with severe impairment of liver function and in dialysis patients. In patients with severe impairment of renal or hepatic function, a changeover to insulin is indicated, not least to achieve optimal metabolic control.
